Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABT Stock Forecast 2026-2027
$98.83
Current Price
$154.95B
Market Cap
Buy 21
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to ABT Price Targets
+36.6%
To High Target of $135.00
+16.4%
To Median Target of $115.00
-6.9%
To Low Target of $92.00
ABT Price Momentum
+5.2%
1 Week Change
+11.7%
1 Month Change
-18.0%
1 Year Change
-21.1%
Year-to-Date Change
-28.1%
From 52W High of $137.49
+20.6%
From 52W Low of $81.97
📊 TOP ANALYST CALLS
Did ABT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Abbott is one of their latest high-conviction picks.
Latest ABT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, ABT has a bullish consensus with a median price target of $115.00 (ranging from $92.00 to $135.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $98.83, the median forecast implies a 16.4% upside. This outlook is supported by 21 Buy, 7 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABT Analyst Ratings
21
Buy
7
Hold
0
Sell
ABT Price Target Range
Low
$92.00
Average
$115.00
High
$135.00
Current: $98.83
Latest ABT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $112.00 |
| Jul 1, 2026 | Baird | David Rescott | Outperform | Initiates | $121.00 |
| Jun 22, 2026 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Apr 27, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 20, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 17, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Apr 17, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 17, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Apr 17, 2026 | Benchmark | Buy | Maintains | $N/A | |
| Apr 17, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Apr 17, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Apr 17, 2026 | Stifel | Buy | Maintains | $N/A | |
| Apr 17, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 9, 2026 | Goldman Sachs | Buy | Maintains | $N/A | |
| Apr 8, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 31, 2026 | BTIG | Buy | Maintains | $N/A | |
| Mar 26, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 11, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 2, 2026 | Barclays | Overweight | Maintains | $N/A |
Abbott Laboratories (ABT) Competitors
The following stocks are similar to Abbott based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Abbott Laboratories (ABT) Financial Data
Abbott Laboratories has a market capitalization of $154.95B with a P/E ratio of 25.0x. The company generates $45.13B in trailing twelve-month revenue with a 13.9% profit margin.
Revenue growth is +7.8% quarter-over-quarter, while maintaining an operating margin of +13.5% and return on equity of +12.3%.
Valuation Metrics
Market Cap
$154.95B
Enterprise Value
$187.92B
P/E Ratio
25.0x
PEG Ratio
-1.3x
Price/Sales
3.4x
Growth & Margins
Revenue Growth (YoY)
+7.8%
Gross Margin
+56.2%
Operating Margin
+13.5%
Net Margin
+13.9%
EPS Growth
-18.7%
Financial Health
Cash/Price Ratio
+4.2%
Current Ratio
1.4x
Debt/Equity
64.8x
ROE
+12.3%
ROA
+5.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Abbott Laboratories (ABT) Business Model
About Abbott Laboratories
What They Do
Healthcare company offering diverse medical products.
Business Model
Abbott Laboratories generates revenue by developing and selling a wide array of medical products and pharmaceuticals across four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company’s diverse product offerings, including medical devices for cardiovascular and neurological conditions, continuous glucose monitors, and nutritional products, cater to various healthcare needs, enabling it to capture a broad market.
Additional Information
Headquartered in Abbott Park, Illinois, Abbott operates in over 160 countries, with approximately 60 percent of its sales coming from international markets. This extensive global presence solidifies its role as a key player in the healthcare industry, serving healthcare professionals, patients, and consumers worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
122,000
CEO
Mr. Robert B. Ford
Country
United States
IPO Year
1983
Website
www.abbott.comAbbott Laboratories (ABT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.
Jul 16, 2026
By Zacks Equity Research
Analyst Blog
Reasons to Retain Abbott Stock in Your Portfolio for Now
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
Jul 15, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
ABT anticipates growth in Q2 across Diagnostics, Devices, and EPD sectors, but expects Nutrition to negatively impact overall results.
Why It Matters
ABT's anticipated growth in key sectors may boost stock performance, while weak Nutrition results could raise concerns, impacting overall investor sentiment and company valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Analysts are assessing Abbott's (ABT) performance for Q2 2026 by evaluating projections for key metrics beyond its revenue and earnings estimates.
Why It Matters
Projections for Abbott's key metrics provide insights into future performance, impacting valuation and investment decisions based on growth expectations and financial health.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
ABT is focusing on growth in emerging-market pharmaceuticals and innovation in Nutrition, though it faces challenges from macroeconomic pressures and currency fluctuations.
Why It Matters
ABT's focus on emerging markets and innovation may boost growth, but macroeconomic challenges and currency volatility could impact profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
4 days ago
Quick Summary
Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE) both exceeded Q1 2026 earnings expectations, but market reactions to their performances have differed.
Why It Matters
Divergent market reactions to Abbott and Pfizer's earnings beats suggest differing investor confidence or growth prospects, impacting stock valuations and investment strategies.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
7 days ago
Quick Summary
Abbott Laboratories and Danaher reported contrasting results for Q1 2026, highlighting differing financial performances.
Why It Matters
Diverging performance between Abbott Laboratories and Danaher signals varying growth prospects, potentially influencing investor sentiment and stock valuations in the healthcare sector.
Source: 24/7 Wall Street
Market Sentiment:
Negative
Quick Summary
Analyst recommendations from brokerage firms can significantly impact stock prices, influencing investor decisions to buy, sell, or hold.
Why It Matters
Analyst recommendations can significantly sway stock prices, impacting investment strategies and market sentiment. Understanding their influence is crucial for making informed trading decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About ABT Stock
What is Abbott Laboratories's (ABT) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Abbott Laboratories (ABT) has a median price target of $115.00. The highest price target is $135.00 and the lowest is $92.00.
Is ABT stock a good investment in 2027?
According to current analyst ratings, ABT has 21 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $98.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABT stock?
Wall Street analysts predict ABT stock could reach $115.00 in the next 12 months. This represents a 16.4% increase from the current price of $98.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Abbott Laboratories's business model?
Abbott Laboratories generates revenue by developing and selling a wide array of medical products and pharmaceuticals across four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company’s diverse product offerings, including medical devices for cardiovascular and neurological conditions, continuous glucose monitors, and nutritional products, cater to various healthcare needs, enabling it to capture a broad market.
What is the highest forecasted price for ABT Abbott Laboratories?
The highest price target for ABT is $135.00 from at , which represents a 36.6% increase from the current price of $98.83.
What is the lowest forecasted price for ABT Abbott Laboratories?
The lowest price target for ABT is $92.00 from at , which represents a -6.9% decrease from the current price of $98.83.
What is the overall ABT consensus from analysts for Abbott Laboratories?
The overall analyst consensus for ABT is bullish. Out of 6 Wall Street analysts, 21 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $115.00.
How accurate are ABT stock price projections?
Stock price projections, including those for Abbott Laboratories, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:01 AM UTC